Weight-loss drugs prescribed to anorexia patients, causing severe harm

Somewhere in the machinery of American medicine, a contradiction has taken root: doctors are prescribing weight-loss drugs to patients whose bodies are already wasting away from anorexia nervosa. The drugs, designed to suppress appetite and accelerate metabolic burn, are being given to people whose central struggle is the inability to eat enough, whose minds tell them their bodies are too large even as those bodies approach crisis. The result is a cascade of harm that clinical guidelines explicitly warn against, yet the practice persists.

Anorexia nervosa is a psychiatric illness with the highest mortality rate of any mental disorder. Patients with this condition experience distorted body image, severe restriction of food intake, and a pathological fear of weight gain. Their bodies become depleted of essential nutrients. Their hearts weaken. Their bones thin. Their organs begin to fail. In this context, a medication designed to further suppress appetite and accelerate weight loss is not treatment—it is acceleration toward danger.

Yet weight-loss drugs are being prescribed to anorexia patients off-label, meaning for uses not approved by the FDA and not supported by clinical evidence. This happens not through malice but through a gap between how these medications are marketed and how they should actually be used. The drugs have become culturally prominent, heavily promoted, and increasingly normalized. Some prescribers appear to be applying them broadly without adequately screening for contraindications. Others may not recognize that a patient presenting with weight concerns might actually be struggling with an eating disorder rather than simple obesity.

The human cost is severe. Patients already vulnerable—already caught in the grip of a disorder that distorts their perception of their own bodies—are given medications that reinforce the very pathology they are fighting. Weight loss accelerates. Malnutrition deepens. Psychological distress intensifies. Some patients report that the drugs validated their eating disorder, providing external medical authority for the restriction they were already imposing on themselves. The medications did not treat their condition; they weaponized it.

This represents a failure at multiple levels. Pharmaceutical companies market these drugs with intensity and reach, emphasizing weight loss and aesthetic outcomes. Clinical guidelines exist that clearly state weight-loss medications are contraindicated in eating disorders, yet these guidelines have not penetrated all prescribing practices. Screening protocols that should catch eating disorders before weight-loss drugs are dispensed are inconsistent or absent. Patients themselves, already isolated by shame and secrecy around their disorder, may not disclose their eating patterns to prescribers who do not ask the right questions.

The gap between what we know and what is being done in practice is not theoretical—it is measured in worsened health outcomes, in patients whose conditions deteriorated after starting these medications, in families watching their loved ones decline under treatment that was supposed to help. Some patients have required hospitalization. Others have experienced medical emergencies. The drugs did exactly what they were designed to do: they made people lose weight. In the context of anorexia, that is precisely the wrong outcome.

What comes next remains uncertain. Regulatory bodies may tighten oversight. Clinical guidelines may be updated with more forceful language. Prescribers may be required to implement more rigorous screening. But for now, the practice continues—a reminder that even in modern medicine, the distance between knowing what is harmful and preventing that harm can be vast, and that the most vulnerable patients are often the ones who pay the price for that gap.